The Rhode Island-based health care giant also hiked its 2025 forecast well above Wall Street estimates. But it booked a ...

CVS Health management raised 2025 EPS guidance, projecting robust double-digit earnings growth. Click here to read why CVS stock is a Buy.

CVS Health is reevaluating its role in healthcare as financial pressures mount. The company, along with other major retailers, is scaling back its healthcare ambitions in response to economic and ...

What Happened? Shares of diversified healthcare company CVS Health (NYSE:CVS) fell 4.3% in the morning session after the company reported a significant $5.7 billion goodwill impairment charge related ...

CVS Health projected double-digit earnings growth for 2026 on Wednesday after raising its 2025 profit forecast for the third ...

High-rolling investors have positioned themselves bearish on CVS Health (NYSE:CVS), and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's ...

The look of the health and wellness products at CVS is about to get a little less prescriptive. The pharmacy chain, which reported $94.59 billion in revenue in the first quarter of 2025, landing ahead ...

CVS Health is rolling out a new customer app that aims to make it simpler and more convenient for users to manage health benefits, pharmacy benefits and prescriptions. Within the application, users ...

CVS Health, which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences’ new HIV prevention drug to its commercial plans for now, a spokesperson told Reuters, despite the ...

CVS Health rode double-digit sales growth from drugstores and its pharmacy benefits management business to a ...

CVS topped low expectations on the top and bottom lines in the fourth quarter. Profits are expected to rebound in 2025. The stock is cheap at a forward P/E of less than 11. CVS, which operates the ...